Nano Retina Inc.
Latest From Nano Retina Inc.
The neuromodulation market is growing at a rapid pace and investors and strategics are paying close attention to early-stage innovators. We highlight Cardionomic, Nuviant and Pixium, three young companies that are listening to the brain, fixing broken hearts and making the blind see.
Neurostimulation technology is migrating into the ophthalmology field, and the implications could be significant for the millions of patients worldwide with degenerative eye diseases, including retinitis pigmentosa and age-related macular degeneration, as well as those with moderate-to-severe dry eye disease. Companies active in this space include Second Sight Medical Products, Retina Implant AG, Pixium Vision, Nano Retina, and many others.
On many fronts, 2011 was an event-filled year for the retinal disease market, beginning with the publication of the CATT trial comparing off-label intravitreal Avastin versus Lucentis for the treatment of AMD, and ending with several important milestones for device manufacturers operating in this space. But while the retinal device field is making progress in many areas, companies continue to struggle to meet shifting FDA approval requirements.
Noteworthy news from medtech start-ups. This month we profile three emerging artificial retina developers: Nano Retina, 2C Tech Corp. and LambdaVision.
- Implantable Devices
- Therapeutic Areas
- Middle East
- Parent & Subsidiaries
- Nano Retina Inc.
- Senior Management
- Ra'anan Gefen, Managing Dir.
- Contact Info
Nano Retina Inc.
Phone: (972) 09 9701840
85 Medinat Hayehudim St., Bus. Park
Bldg. G,8th Fl.
Herzeliya Pituach, 46140
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.